Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


June 30, 2015 10:08 AM ET

Biotechnology

Company Overview of Galena Biopharma, Inc.

Company Overview

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products include Abstral, a sublingual tablet that is used for the management of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of emetogenic chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting. The company’s lead product candidate comprise NeuVax (nelipepimut-S), which is in Phase III clinical trials for use in the prevention of recurrence in early- stage and node-positive breast cancer with low to intermediate human ...

4640 SW Macadam Avenue

Suite 270

Portland, OR 97239

United States

Founded in 2003

57 Employees

Phone:

855-855-4253

Fax:

503- 400-6611

Key Executives for Galena Biopharma, Inc.

Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Age: 59
Total Annual Compensation: $707.1K
Chief Financial Officer and Vice President
Age: 44
Total Annual Compensation: $299.4K
Consultant
Age: 49
Total Annual Compensation: $145.5K
Compensation as of Fiscal Year 2014.

Galena Biopharma, Inc. Key Developments

Galena Biopharma, Inc. Announces Executive Changes

On June 24, 2015, Galena Biopharma, Inc. entered into a separation and consulting agreement with Margaret Kivinski pursuant to which her employment as Vice President and General Counsel was terminated on June 18, 2015 and under which she agrees to consult with the company regarding the legal aspects of business and operations for a six-month period commencing on June 18, 2015 and ending on December 18, 2015, unless the separation and consulting agreement is sooner terminated as provided therein. On June 24,2015, Thomas J. Knapp accepted employment offer letter to serve as interim General Counsel for the six-month period commencing on June 25, 2015 and ending on December 31, 2015. Until recently, Mr. Knapp served as the Executive Vice President, Chief Legal Officer and Corporate Secretary of Sucampo Pharmaceuticals, Inc. He will continue to serve as a consultant to Sucampo Pharmaceuticals, Inc. through August 2015.

Galena Biopharma, Inc. Approves Amendment to Amended and Restated Certificate of Incorporation

Galena Biopharma, Inc. announced that at the annual meeting held on June 19, 2015 approved an amendment to amended and restated certificate of incorporation to increase the number of shares of common stock authorized for issuance by 75,000,000 shares, to a total of 275,000,000 shares.

Galena Biopharma, Inc. Presents Phase 2 Clinical Trial of Gale-401 at the European Hematology Association 20th Congress in Vienna, Austria

Galena Biopharma, Inc. announced that data from the Company's Phase 2 clinical trial of GALE-401 was presented at the European Hematology Association 20th Congress in Vienna, Austria. The GALE-401 Phase 2 pilot study is a single arm, open label, multi-center study evaluating the efficacy and safety of anagrelide controlled release in subjects with thrombocytosis secondary to essential thrombocythemia (ET) and other myeloproliferative neoplasms (MPNs). The primary objective of the study was to estimate ORR with the secondary objectives of safety, tolerability and pharmacokinetics (PK). Enrolled patients were adult men and women diagnosed with an MPN-related elevated platelet count to include chronic myelogenous leukemia (CML), polycythemia vera (PV), primary myelofibrosis (PMF), or ET.

Similar Private Companies By Industry

Company Name Region
Signum Biosciences, Inc. United States
NAT Diagnostics, Inc. United States
Microbes BioSciences, Inc. United States
LC Sciences, LLC United States
Click Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Galena Biopharma, Inc., please visit www.galenabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.